Burn treatment company MediWound's stock soars amid Israel's war in Gaza
The company expects to generate $24 million in sales this year, up from $19 million in 2023
Stay updated with breaking news from Ofer Gonen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company expects to generate $24 million in sales this year, up from $19 million in 2023
If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S. NexoBrid is already approved for use for burn patients across all age groups in Europe and Japan YAVNE, Israel, Jan. 09, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Food and Drug Administration (FDA) has completed the
In a groundbreaking partnership with the US Department of Defense and MTEC, MediWound's NexoBrid emerges as a beacon of hope, revolutionizing burn treatment and arming soldiers with a swift, non-invasive lifeline against the brutal realities of war.
Biotherapeutics company MediWound has secured an additional $6.7 million in funding from the US Department of Defense to advance its non-surgical burn treatment for the US Army.
28.12.2023 - Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 millionYAVNE, Israel, Dec. 28, 2023 (GLOBE NEWSWIRE) - MediWound Ltd. (Nasdaq: MDWD), a fully-integrated ... Seite 1